Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease of the central
nervous system that leads to blindness and paralysis. Since disability accrues incrementally
related to attacks, attack prevention with immunosuppressive therapy is the mainstay of
preventing disability. However, there is no standard immunosuppressive treatment strategy for
NMO relapse prevention. In a previous study, the investigators provided evidence supporting
the use of azathioprine plus a low dose corticosteroid as an effective strategy which is
associated with a reduction in the risk of relapse in Chinese patients with NMO, but
azathioprine has bone marrow suppression and other side effects. Mycophenolate mofetil (MMF)
is a new immunosuppressant with rapid onset, fewer side effects and other advantages. In
recent years, MMF has been used in different immune-related neurological diseases; some
literature shown the possible efficacy of MMF in NMO treatment.
In this research, a multi-center (Third Affiliated Hospital of Sun Yat-sen University,
Zhongshan Ophthalmic Centre of Sun Yat-sen University, Nangfang Hospital of Southern Medical
University) study will carry out to evaluate the efficacy and safety of mycophenolate mofetil
therapy in NMO spectrum disorders.
Phase:
Phase 4
Details
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Collaborators:
Nangfang Hospital, Southern Medical University Southern Medical University, China Zhongshan Ophthalmic Center, Sun Yat-sen University Zhongshan Ophthalmic Center, Sun Yet-san University